$STX

BHATT PRAT sold $930K of STX

BHATT PRAT sold 1,000 shares of Seagate Technology Holdings plc (STX) at $929.88 ($0.93M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BHATT PRAT
Published Jun 2, 2026, 9:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
medium confidence
Mentioned
$STX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

The disclosure updates insider activity records but does not introduce new company fundamentals (no earnings, guidance, deal, or regulatory action).

02

Market read

Primarily a sentiment/positioning datapoint; likely low incremental trading impact absent follow-on catalysts.

03

What to watch

The sale size is modest and explicitly pre-arranged; without additional context (e.g., multiple concurrent sales, changes in trading plans), the signal may be overstated.

Relevance 6/10Novelty 6/10Timing: Filed same day as the open-market sale (2026-06-02)

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by a director under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$STXNeutralMedium confidence
Context

Seagate director BHATT PRAT sold 1,000 shares in an open-market transaction at ~$929.88 on a 10b5-1 plan, updating insider supply signals.

Expected impact

Likely limited/short-lived impact; watch for any follow-on insider activity or unusual volume around the sale date.

Evidence & confidence

The filing is a routine Form 4 with a stated pre-arranged 10b5-1 plan; the disclosed sale size is small relative to a mega-cap, and no new operating/financial catalyst is provided.

Market effects

Minimal; this is company-specific insider liquidity disclosure without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

If the market interprets repeated insider sales as a risk signal, STX could see mild sentiment pressure despite the 10b5-1 framing.

Key entities

  • Seagate Technology Holdings plc

    STX insider transaction disclosed via SEC Form 4: director BHATT PRAT sold 1,000 shares at ~$929.88 on 2026-06-02 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.